2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160436
    TNF-α-IN-15 364039-58-7 98%
    TNF-α-IN-15 is a TNF-α inhibitor. TNF-α-IN-15 can decrease the TNF-α blood levels.
    TNF-α-IN-15
  • HY-160437
    TNF-α-IN-16 364039-60-1 98%
    TNF-α-IN-16 is a potent TNFα inhibitor with an IC50 of <0.6 μM. TNF-α-IN-16 has antiinflammatory properties (WO2001072735A2; example 18).
    TNF-α-IN-16
  • HY-160545
    NLRP3-IN-31 2769040-08-4 98%
    NLRP3-IN-31 (Comp 14) is a NLRP3 inhibitor, with an IC50 of 0.3-0.5 μM.
    NLRP3-IN-31
  • HY-160548
    mTOR inhibitor-18 2170358-67-3 98%
    mTOR inhibitor-18 (Example 106) is a mTOR inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    mTOR inhibitor-18
  • HY-160550
    DPM-1003 3018836-86-4 98%
    DPM-1003 is a PTP1B conformational inhibitor that targets the non-catalytic, disordered segment at the C-terminus of the PTP1B protein, showing improvement in lung inflammation in mice.
    DPM-1003
  • HY-160585
    PD-L1/PD-1-IN-1 2753642-49-6 98%
    PD-L1/PD-1-IN-1 (compound 8j) is a potent inhibitor of PD-L1/PD interaction, with IC50 ＜ 1 nM. PD-L1/PD-1-IN-1 plays an important role in anti-tumor research.
    PD-L1/PD-1-IN-1
  • HY-160634
    BRD4 Inhibitor-31 1446233-35-7 98%
    BRD4 Inhibitor-31 (Example 136) is a BRD4 inhibitor (Kis: 0.234 μM and 0.295 μM for BRD4 BD1 and BRD4 BD2 respectively). BRD4 Inhibitor-31 can be used for research of inflammatory diseases, cancer, and AIDS.
    BRD4 Inhibitor-31
  • HY-160637
    Lp-PLA2-IN-17 1818842-74-8 98%
    Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA2. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA2.
    Lp-PLA2-IN-17
  • HY-160645
    P2X4 antagonist-1 2055601-42-6 99.89%
    P2X4 antagonist-1 (Compound 24) is an antagonist for P2X4 with IC50 of 15 nM.
    P2X4 antagonist-1
  • HY-160646
    LTA4H-IN-3 2707473-09-2 98%
    LTA4H-IN-3 (compound 9) is a LTA4H inhibitor with the IC50 of 28 nM.
    LTA4H-IN-3
  • HY-160654
    IRAK4 modulator-1 1356014-97-5 98%
    IRAK4 modulator-1 (example 161) is a modulator of IRAK4 with IC50=4.647 μM. IRAK4 modulator-1 can be used to study IRAK-mediated disorders.
    IRAK4 modulator-1
  • HY-160663
    Nav1.7 blocker 1 1426336-36-8 98%
    Nav1.7 blocker 1 (example 41) is a Na+ channel (Nav) blocker with an IC50 value of 0.037 μM. Nav1.7 blocker 1 can be used for the study of pain, including neuropathic pain, postoperative pain, inflammatory pain, and so on.
    Nav1.7 blocker 1
  • HY-160676
    sEH-IN-1 1061377-99-8 98%
    sEH-IN-1 (example 67) is a soluble epoxide hydrolase (sEH) inhibitor. sEH-IN-1 can be used in the research of sEH-mediated diseases such as hypertension, cardiovascular disease, inflammation, diabetes, and so on.
    sEH-IN-1
  • HY-160761
    K-Opioid receptor agonist-1 1816990-29-0 98%
    K-Opioid receptor agonist-1 (Compound 5a) is an agonist for κ-Opioid receptor with Ki of 0.25 nM and EC50 of 2 nM. K-Opioid receptor agonist-1 is blood brain barrier (BBB) penetrate (brain/plasma ratios of 0.50 to 0.65). K-Opioid receptor agonist-1 exhibits anti-inflammatory activity in dermatitis models induced by Arachidonic acid (HY-109590) or oxazolidinone.
    K-Opioid receptor agonist-1
  • HY-160980
    Sornidipine 95105-77-4 98%
    Sornidipine is a calcium channel blocker. Sornidipine also reduces neurogenic inflammation. Sornidipine reduces the inflow of calcium ions into cells by blocking L-type calcium channels, thereby reducing the contraction of vascular smooth muscle, leading to vasodilation and decreased blood pressure. Sornidipine can be used to study the cardiovascular system especially in hypertension and related cardiovascular diseases.
    Sornidipine
  • HY-160998
    YM-344031 671204-98-1 98%
    YM-344031 is an orally active antagonist for CCR3. YM-344031 inhibits binding of Eotaxin-1 and RANTES to CCR3, with IC50 of 3.0 and 16.3 nM. YM-344031 inhibits ligand-induced rise in intracellular Ca[2+] and the ligand-induced chemotaxis. YM-344031 inhibits eotaxin-1-induced changes in eosinophil morphology in macaques blood, and prevents allergic skin reactions in a mouse allergy model.
    YM-344031
  • HY-161004
    AMOZ-CH-acid 1416047-56-7 98%
    AMOZ-CH-acid (Hapten 5) is an immunizing and heterologous hapten. AMOZ-CH-acid and ovalbumin conjugate is a coating antigen that improves assay sensitivity.
    AMOZ-CH-acid
  • HY-161006
    TETS-C4-acid 98%
    TETS-C4-acid (Compound 2d) is a hapten coupled directly to a carrier protein through a carboxylic acid functionality. TETS-C4-acid (Compound 2d) can be used to detect tetramethylenedisulfotetramine (TETS).
    TETS-C4-acid
  • HY-161019
    JAK1/TYK2-IN-4 2734918-33-1 98%
    JAK1/TYK2-IN-4 is a dual inhibitor of JAK and TYK2, with IC50s of 39 nM and 21 nM, respectively. JAK1/TYK2-IN-4 has oral bioavailability.
    JAK1/TYK2-IN-4
  • HY-161026
    JM-9 98%
    JM-9 is a inhibitor of MD2. JM-9 suppresses high glucose and palmitic acid -induced inflammation in MPMs. JM-9 improves diabetic kidney disease by inhibiting MD2-mediated inflammation.
    JM-9
Cat. No. Product Name / Synonyms Application Reactivity